40 results about "Reducing anxiety" patented technology

A method for improving the bioavailability of a bioactive substance includes subjecting the bioactive substance to laser radiation. The laser radiation modifies the bioactive substance to thereby modify reactions relating thereto in the body. The method enables reductions in inflammation associated with autoimmune diseases, modification of reaction by-products in the body, increased homogenization and flattening of molecular shape and improved methylation. The improved methylation can be utilized to reduce homocysteine blood levels, and to reduce anxiety, depression, paranoia, hostility, somatization (perception of bodily distress) and obsessive-compulsive symptoms. Enhanced nitric oxide generation from modified L-arginine can be used to reduce systolic and diastolic blood pressure, lower total and LDL cholesterol levels, and improve the ratio of total to HDL cholesterol. Increased depth of penetration of sparse constructive nodes of laser radiation may increase the range of photodynamic therapy applications and a wide range of in vitro and in vivo modifications of molecular shape and activity. Laser acoustic resonance can be utilized to increase the homogeneity of crystals, or favor the generation of novel or preferred crystalline forms.

The present invention is directed to the production of PKC isozyme epsi (PKCepsi)-deficient cells and non-human animals. The present invention is further directed to the identification of PKCepsi as a target for drugs that reduce anxiety. According to the present invention, PKCepsi-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKCepsi to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKCepsi, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors. Additional aspects of the present invention are diagnostic methods for identifying individuals at risk for becoming alcoholics or abusers of other drugs and kits for performing such diagnostic methods. The present invention relates to: cells and non-human animals deficient for the PKC isozyme epsi (PKCepsi); the use of PKCepsi as a target for drugs; the use of inhibitors of PKCepsi in methods of reducing anxiety and treating conditions associated with insufficient activity of the GABAA receptor; the use of modulators of PKCepsi in methods of modulating alcohol consumption, modulating self-administration of other drugs of abuse, and altering the effects of alcohol; pharmaceutical compositions comprising inhibitors of PKCepsi and allosteric agonists of GABAA receptors; and the identification of individuals with enhanced susceptibility to alcoholism or other forms of addiction.

Disclosed are methods comprising: receiving data representing the physical location, movement, social environment, emotional state and nutritional behavior; comparing this data and nutritional behaviors throughout the day to goals for achieving a balance of macronutrients (food groups) and micronutrients, represented by a Nutrition Score; determining the positive and negative impact of physical and social environment on nutritional behaviors and emotional state; targeting messages, cues, tips and coping tactics based on acquired parameters to help change the individuals response to the environment and other factors, improve mood, reduce anxiety and improve nutritional behavior; and allowing for real-time connectivity to a support system. Also disclosed are methods where the acquired parameters are transmitted to health care professionals, such as dietitians, therapists, physicians, health coaches, through real-time connectivity to acquired parameters, health professionals can more effectively coordinate and target care.

The present invention is designed to prevent or reduce anxiety in child or adolescent patients undergoing dental or medical procedures through a design to conceal or hide elements of a traditional syringe. The use of an opaque sleeve or exterior surface shaped in a manner other than a tube is used to conceal the interior of the syringe barrel, mask the plunger, and partially obstruct the view of the cannula assembly.

Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and / or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and / or galactooligosaccharides.

A garment to reduce an animal's anxiety, fearfulness, overexcitement, or a combination thereof. The garment may include a central portion, flaps extending from opposite sides of the central portion, and, in some cases, a cinching member that extends from a central area of the central portion. The flaps may be fastened together around the chest and stomach of the animal, and the cinching member may be fastened to the central portion or one or more flaps to tighten the garment further, applying pressure to reduce anxiety, fearfulness, or over-excitement. Straps may be provided to secure the garment to the animal's neck. One material that may be used in making the garment is a fabric made of 55% cotton, 35% polyester, and 10% spandex. The animal may generally be any animal with four legs, for example, a dog or cat, or two arms and two legs, for example, a monkey.

Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C1-C4 alkoxy group, or their precursor compounds, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to calm and / or reduce anxiety and related behaviors and states in humans and animals. Additional chemical compounds of the present invention may include benzoxazinoids-cyclic hydroxyamic acids, lactams, and corresponding glucosides, which may serve as precursors to phenolic compounds. The phenolic compounds and precursors of phenolic compounds of the present invention, at concentrations suitable for human and animal therapeutic use, may be obtained from monocotyledonous plants such as corn in their early growth states which are timely harvested for optimum yield.

A system and method for reducing anxiety of a patient during medical scanning in a medical scanner which may produce significant levels of acoustic noise. A processor or control unit receives a measure of variation in a parameter of the scanner noise during the medical scanning. The processor then generates outputs to audio and video playback units that present an audio-video scenery to the patient during the scanning in accordance with the measure of variation in the parameter of the scanner noise. An image object in the video imagery is linked to the audio signal, so as to distract the patient's attention away from the scanner noise. The audio-video scenery may be switched according to an estimated scanner noise level. An effective distraction of the patient is obtained with a limited audio signal level which is far lower than the scanner noise.

Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and / or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood βHB levels and changed blood glucose levels.

Compositions are described comprising at least partially defatted meal from a plant source containing protein-bound tryptophan, preferably squash seeds, and, optionally, a carbohydrate source provided in an amount capable of facilitating transport of in vivo generated tryptophan across the blood brain barrier. Also described are dietary supplements, foods and beverages comprising the composition of the invention to reduce anxiety.

Described are reminiscence therapy and media sharing platform, methods, and systems for a patient user which provide an immediate and First Mobile Application positive impact on emotional functioning inpatients with dementia, major neurocognitive disorders, social isolation, traumatic brain injury (TBI), and psychiatric conditions such as posttraumatic stress disorder, by reducing anxiety, depression, and overall emotional distress.

The invention provides a medicament for treating irritable bowel syndrome with spleen-stomach damp-heat syndrome, comprising medicinal materials: Radix Scutellariae, Rhizoma Coptidis, Herba Portulacae, Radix Sophorae Flavescentis, Radix Pulsatillae, Rhizoma Atractylodis, Semen Coicis, Poria, Radix Puerariae, Radix Curcumae, Fructus Aurantii, Rhizoma Cyperi, Pericarpium Citri Reticulatae, Pericarpium Citri Reticulatae, Cortex Magnoliae Officinalis, Radix Notoginseng, Radix Paeoniae Alba, Radix Paeoniae Rubra, Fructus Crataegi, Herba Lophatheri, Rhizoma Acori Tatarinowii and Radix Glycyrrhizae Preparata. The medicament is effective in clearing heat and eliminating damp, relieving spasm and pain and cooling blood and removing stasis through formulation compatibility with respect to traditional Chinese medicine differentiation of the irritable bowel syndrome with spleen-stomach damp-heat syndrome in connection with clinical manifestation of a patient. The medicament is well functional in treating a patient with the irritable bowel syndrome with spleen-stomach damp-heat syndrome in terms of clinical symptoms and living quality; can reduce recurrence of this disease, thus reducing anxiety and depression.

The present invention is directed to the production of PKC isozyme epsilon (PKCepsilon)-deficient cells and non-human animals. The present invention is further directed to the identification of PKCepsilon as a target for drugs that reduce anxiety. According to the present invention, PKCepsilon-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKCepsilon to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKCepsilon, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors. Additional aspects of the present invention are diagnostic methods for identifying individuals at risk for becoming alcoholics or abusers of other drugs and kits for performing such diagnostic methods. The present invention relates to: cells and non-human animals deficient for the PKC isozyme epsilon (PKCepsilon); the use of PKCepsilon as a target for drugs; the use of inhibitors of PKCepsilon in methods of reducing anxiety and treating conditions associated with insufficient activity of the GABAA receptor; the use of modulators of PKCepsilon in methods of modulating alcohol consumption, modulating self-administration of other drugs of abuse, and altering the effects of alcohol; pharmaceutical compositions comprising inhibitors of PKCepsilon and allosteric agonists of GABAA receptors; and the identification of individuals with enhanced susceptibility to alcoholism or other forms of addiction.

The invention discloses a virtual training system and method based on virtual agent interaction. The invention allows users to select different interaction types, different situations and different personality characteristics of virtual questioners for interview training according to their own needs or training goals, and can meet various requirements. The presentation of specific anxiety situations and personalized training needs; the use of 3D glasses and stereo projection to present a simulated virtual training environment, and the direct voice interaction with the virtual questioner through Bluetooth headsets to achieve a natural and immersive interview experience; multiple interviews during the interview Modal perception, including action recognition, emotion recognition and physiological state recognition, to better understand the user's interview status. This system does not require expensive virtual reality equipment, and users can effectively reduce anxiety and improve communication skills through repeated training.

The present invention provides methods, compositions, and kits for treating anxiety -related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.

A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.

Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and / or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood βHB levels and changed blood glucose levels.

A supplement that produces an increased feeling of alertness and reduces anxiety, or produce a feeling of calmness is described. In an exemplary embodiment, the supplement is all natural, and contains no or essentially no synthesized chemical. The supplement or the therapeutic ingredients, such as the ingredients within a capsule, may only contain plant matter. The plant matter may include plant roots and leaves, for example. The supplement and more specifically the active ingredient of the supplement may include, piper methysticum (kava kava root), brahmi (bacopa), ashwagandha (winter cherry). These three ingredients may be the primary active or therapeutic ingredients and may be provided in an effective amount to produce a feeling of alert calmness.